Analysts' Insights on ICU Medical Stock
Analyst Ratings Overview: Recent evaluations of ICU Medical by four analysts show a mix of bullish and bearish sentiments, with a total of one bullish and three somewhat bullish ratings in the last 30 days, reflecting a shift in outlook compared to previous months.
Price Target Adjustments: Analysts have lowered the average price target for ICU Medical to $162.75, down 6.64% from prior estimates, with a high target of $180.00 and a low of $145.00.
Company Performance Metrics: ICU Medical faces revenue growth challenges, experiencing a decline of approximately 7.98% over the last three months, while maintaining strong profitability with a net margin of 6.44% and a return on equity of 1.72%.
Debt Management and Market Position: The company has a below-average debt-to-equity ratio of 0.66, indicating prudent financial management, but its market capitalization is below industry benchmarks, suggesting potential growth limitations compared to peers.
Trade with 70% Backtested Accuracy
Analyst Views on ICUI
About ICUI
About the author
ICU Medical to Present Innovative Products at 44th Annual J.P. Morgan Healthcare Conference
- Conference Participation: ICU Medical will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 1:30 PM PT, showcasing its innovations in medical products, which is expected to attract significant investor interest.
- One-on-One Meetings: The management team will also engage in one-on-one meetings on the same day, aiming to deepen connections with potential investors and foster future capital collaborations, enhancing the company's market presence.
- Live Webcast: The presentation will be webcast live on the company's website, allowing viewers to access and replay the session, which increases transparency and broadens its influence in the healthcare sector.
- Company Background: ICU Medical focuses on the development and sale of infusion systems and high-value critical care products, committed to providing quality and innovation to clinical customers worldwide, underscoring its leadership position in the medical industry.
Insiders Purchase Shares of VHT ETF Holdings
Insider Buying in Vanguard Health Care ETF: 17.6% of the weighted holdings in the Vanguard Health Care ETF (VHT) have seen insider buying in the past six months.
ICU Medical Inc Activity: ICU Medical Inc (ICUI), making up 0.05% of VHT, has had two directors and officers purchase shares recently, with the ETF holding $9,411,006 worth of ICUI.
Tandem Diabetes Care Inc Activity: Tandem Diabetes Care Inc (TNDM), the #243 largest holding in VHT, also shows insider buying from two directors and officers, with the ETF holding $3,407,114 worth of TNDM.
Disclaimer: The views expressed in the article are those of the author and do not necessarily reflect those of Nasdaq, Inc.
